POLB 001 data to be presented at ASH

Poolbeg Pharma

06/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241106:nRSF0766La&default-theme=true

RNS Number : 0766L  Poolbeg Pharma PLC  06 November 2024

REACH

 

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th
American Society of Hematology (ASH) Annual Meeting

 

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model

 

Positive results reinforce POLB 001's potential in the prevention and
treatment of cancer immunotherapy-induced CRS

 

ASH is the world's premier conference focussing on haematological malignancies

 

6 November 2024 - Poolbeg Pharma
(https://url.avanan.click/v2/___https:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86OWNmMWY1N2E1OGNjMTQ0YjY4M2Q3ODBjNThiMDY0YjU6NjplNzkyOmE3NTIxZDAzYzhiMjczMzk2ZTQxMDMwZjhhZWExYzNiMDkyM2YwZjNiMmFjZjVjMmE5NTYxNzA1MWMyOTBhNGE6cDpGOk4)
 (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company focussed on the development and commercialisation of innovative
medicines targeting diseases with a high unmet medical need, today announces
that it will present a poster detailing POLB 001's efficacy in reducing
immunotherapy-induced CRS in an in vivo animal model, at the 66th American
Society of Hematology ('ASH') Annual Meeting and Exposition, taking place
7-10 December 2024 in San Diego, California.

Poolbeg's poster presentation will provide insights into the results obtained
from a POLB 001 in vivo study, a mouse model of immunotherapy-induced CRS.
The positive results highlighted POLB 001's potential in the prevention and
treatment of cancer immunotherapy-induced CRS. CRS can occur in >70% 1  of
patients treated with T cell engaging bispecific antibodies, or CAR T cell
therapies. CRS of any grade can lead to prolonged hospital stays and mortality
risk. The administration of these cancer immunotherapies is therefore
restricted only to specialist cancer centres, which has created a "bottleneck"
in providing seamless, cost-efficient access to these treatments for the
patients who need them.

Mark Sumeray MD, Consultant Clinical Advisor for Poolbeg, commented: "These
data underscore the potential for POLB 001 to prevent or reduce the severity
of CRS. If this effect is demonstrated in the clinic, this would enable
broader, safer delivery of cancer immunotherapies, including in an out-patient
setting. We look forward to sharing these important findings with the global
hematology community at ASH."

 

Title: POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome
(CRS) in a Mouse Model of Immunotherapy-Induced CRS

Session Name: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and
Translational: Poster I

Session Date and Time: Saturday, 7 December 2024, 5:30 PM - 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

Authors:  Liam Tremble, PhD, MSc, BSc, Paula Maguire, PhD, Jiwon Yang, PhD,
James G Keck, Laura Maher, MSc, Mark Graham, Martin F Kaiser, MD, FRCP,
FRCPath, Emma Searle, MD, PhD and Mark Sumeray, MD

Abstract Number: 2061

To schedule a meeting with the Company, please contact
partnering@poolbegpharma.com.

 

 

Enquiries

 

 Poolbeg Pharma Plc                                                  +44 (0) 207 183 1499

 Jeremy Skillington, CEO                                             ir@poolbegpharma.com

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (NOMAD & Joint Broker)                +44 (0) 207 220 0500

 Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                       +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory)

Malachy McEntyre, Isobel Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                             +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                    +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                             poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on
acquiring, developing and commercialising innovative medicines that will help
improve the lives of patients with rare and orphan diseases and where there is
a high unmet medical need. Poolbeg comprises a strong and growing portfolio of
development assets. For more information, please go to www.poolbegpharma.com
(https://url.avanan.click/v2/___https:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86OWNmMWY1N2E1OGNjMTQ0YjY4M2Q3ODBjNThiMDY0YjU6NjplNzkyOmE3NTIxZDAzYzhiMjczMzk2ZTQxMDMwZjhhZWExYzNiMDkyM2YwZjNiMmFjZjVjMmE5NTYxNzA1MWMyOTBhNGE6cDpGOk4)
 or follow us on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDphOm86OWNmMWY1N2E1OGNjMTQ0YjY4M2Q3ODBjNThiMDY0YjU6NjpjNzI5OmI1NGNiOTc0NWE1MDVlZDVkNzFjMzU4OTEyZTI2MTA3YTZiN2NlNTZlZTA3ZTY5NjU4OTI0YjdiNGJlY2U0YjM6cDpGOk4)
 and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDphOm86OWNmMWY1N2E1OGNjMTQ0YjY4M2Q3ODBjNThiMDY0YjU6NjozYTZiOjYyNmU5OTE5ODJlYmJiMDY0ZDIzNjVhNzY4MmU4MDFlYzc0ODMxZTQzNjQ0NWUxZjE0MDViYmNhMmM1ZjVhMDE6cDpGOk4)
 @PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 1  Average rate from Summary of Product Characteristics (SmPCs) for Yescarta,
Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly,
Tecvayli and Talvey

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFIILTLEIIS